Journal of Clinical Oncology, Vol 7, 1268-1274, Copyright © 1989 by American Society of Clinical Oncology

ARTICLES

On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group

B Lowenberg, R Zittoun, H Kerkhofs, U Jehn, J Abels, L Debusscher, C Cauchie, M Peetermans, G Solbu and S Suciu
Dr Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.

We report the results of a prospective study in patients more than 65 years of age in whom two different therapeutic strategies were compared: immediate intensive-induction chemotherapy (arm A) versus "wait and see" and supportive care and mild cytoreductive chemotherapy only for relief of progressive acute myeloid leukemia (AML)-related symptoms (arm B). The major objective of the study was to compare survival outcome of both regimens. Thirty-one patients on arm A received one or two courses of daunorubicin, vincristine, and cytarabine for remission induction followed by one additional cycle for consolidation in case of complete remission (CR). Among 29 patients on arm B, cytoreductive chemotherapy (hydroxyurea, cytarabine) had to be initiated for palliation of leukemia-associated complications in 21 patients at a median of 9 days after diagnosis. Overall survival duration for patients treated on arm A was significantly (P = .015) longer than the survival in arm B (median survival, 21 weeks v 11 weeks; projected survival at 2.5 years, 13% v 0%). Eighteen (58%) of arm A patients and none (0%) of arm B patients entered CR. Of the first group, projected disease-free survival at 2 years is 17%. The median percentages of days spent in the hospital by arm A and B patients were 55% and 50%, respectively. This study shows that a strategy based on modern supportive care and a wait and see approach yields extremely poor results. It is not superior in regard to the frequency of hospital admission and is inferior regarding survival outcome.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H. Dohner, E. H. Estey, S. Amadori, F. R. Appelbaum, T. Buchner, A. K. Burnett, H. Dombret, P. Fenaux, D. Grimwade, R. A. Larson, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet Blood, January 21, 2010; 115(3): 453 - 474. [Abstract] [Full Text] [PDF]

				A. V. Rao, P. J.M. Valk, K. H. Metzeler, C. R. Acharya, S. A. Tuchman, M. M. Stevenson, D. A. Rizzieri, R. Delwel, C. Buske, S. K. Bohlander, et al. Age-Specific Differences in Oncogenic Pathway Dysregulation and Anthracycline Sensitivity in Patients With Acute Myeloid Leukemia J. Clin. Oncol., November 20, 2009; 27(33): 5580 - 5586. [Abstract] [Full Text] [PDF]

				B. Lowenberg, G. J. Ossenkoppele, W. van Putten, H. C. Schouten, C. Graux, A. Ferrant, P. Sonneveld, J. Maertens, M. Jongen-Lavrencic, M. von Lilienfeld-Toal, et al. High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia N. Engl. J. Med., September 24, 2009; 361(13): 1235 - 1248. [Abstract] [Full Text] [PDF]

				G. Juliusson, P. Antunovic, A. Derolf, S. Lehmann, L. Mollgard, D. Stockelberg, U. Tidefelt, A. Wahlin, and M. Hoglund Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry Blood, April 30, 2009; 113(18): 4179 - 4187. [Abstract] [Full Text] [PDF]

				H. D. Klepin and L. Balducci Acute Myelogenous Leukemia in Older Adults Oncologist, March 1, 2009; 14(3): 222 - 232. [Abstract] [Full Text] [PDF]

				E. Morra, G. Barosi, A. Bosi, F. Ferrara, F. Locatelli, M. Marchetti, G. Martinelli, C. Mecucci, M. Vignetti, and S. Tura Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation Haematologica, January 1, 2009; 94(1): 102 - 112. [Abstract] [Full Text] [PDF]

				M. A. Sekeres, P. Elson, M. E. Kalaycio, A. S. Advani, E. A. Copelan, S. Faderl, H. M. Kantarjian, and E. Estey Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients Blood, January 1, 2009; 113(1): 28 - 36. [Abstract] [Full Text] [PDF]

				J. J Kishel and J. Sivik Breakthrough invasive fungal infection in an immunocompromised host while on posaconazole prophylaxis: an omission in patient counseling and follow-up Journal of Oncology Pharmacy Practice, December 1, 2008; 14(4): 189 - 193. [Abstract] [PDF]

				J. Laubach and A. V. Rao Current and Emerging Strategies for the Management of Acute Myeloid Leukemia in the Elderly Oncologist, October 1, 2008; 13(10): 1097 - 1108. [Abstract] [Full Text] [PDF]

				M. Yanada, G. Garcia-Manero, G. Borthakur, F. Ravandi, H. Kantarjian, and E. Estey Relapse and death during first remission in acute myeloid leukemia Haematologica, April 1, 2008; 93(4): 633 - 634. [Full Text] [PDF]

				D. Pulte, A. Gondos, and H. Brenner Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century Haematologica, April 1, 2008; 93(4): 594 - 600. [Abstract] [Full Text] [PDF]

				C. Gardin, P. Turlure, T. Fagot, X. Thomas, C. Terre, N. Contentin, E. Raffoux, S. de Botton, C. Pautas, O. Reman, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy:results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial Blood, June 15, 2007; 109(12): 5129 - 5135. [Abstract] [Full Text] [PDF]

				E. Estey Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients J. Clin. Oncol., May 10, 2007; 25(14): 1908 - 1915. [Abstract] [Full Text] [PDF]

				J. E. Lancet, I. Gojo, J. Gotlib, E. J. Feldman, J. Greer, J. L. Liesveld, L. M. Bruzek, L. Morris, Y. Park, A. A. Adjei, et al. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia Blood, February 15, 2007; 109(4): 1387 - 1394. [Abstract] [Full Text] [PDF]

				H. P. Erba Prognostic Factors in Elderly Patients with AML and the Implications for Treatment Hematology, January 1, 2007; 2007(1): 420 - 428. [Abstract] [Full Text] [PDF]

				H. C. Schouten Home treatment for intensive hematological therapies: who will benefit? Ann. Onc., May 1, 2006; 17(5): 731 - 732. [Full Text] [PDF]

				M.-T. Krauth, S. Florian, A. Bohm, K. Sonneck, H. Agis, P. Samorapoompichit, A. W. Hauswirth, W. R. Sperr, and P. Valent Immunological Characterization and Antibacterial Function of Persisting Granulocytes in Leukemic Patients Receiving Pulse Cytosine Arabinoside-Consolidation Chemotherapy on Days 1, 3, and 5 J. Immunol., February 1, 2006; 176(3): 1759 - 1768. [Abstract] [Full Text] [PDF]

				M. S. Tallman, D. G. Gilliland, and J. M. Rowe Drug therapy for acute myeloid leukemia Blood, August 15, 2005; 106(4): 1154 - 1163. [Abstract] [Full Text] [PDF]

				C.-C. Chen, C.-F. Yang, M.-H. Yang, K.-D. Lee, W.-K. Kwang, J.-Y. You, Y.-B. Yu, C.-H. Ho, C.-H. Tzeng, W.-K. Chau, et al. Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia Ann. Onc., August 1, 2005; 16(8): 1366 - 1373. [Abstract] [Full Text] [PDF]

				W. R. Sperr, M. Piribauer, F. Wimazal, C. Fonatsch, R. Thalhammer-Scherrer, I. Schwarzinger, K. Geissler, P. Knobl, U. Jager, K. Lechner, et al. A Novel Effective and Safe Consolidation for Patients Over 60 Years with Acute Myeloid Leukemia: Intermediate Dose Cytarabine (2 x 1 g/m2 on Days 1, 3, and 5) Clin. Cancer Res., June 15, 2004; 10(12): 3965 - 3971. [Abstract] [Full Text] [PDF]

				R. M. Stone, M. R. O'Donnell, and M. A. Sekeres Acute Myeloid Leukemia Hematology, January 1, 2004; 2004(1): 98 - 117. [Abstract] [Full Text] [PDF]

				R. M. Stone The Difficult Problem of Acute Myeloid Leukemia in the Older Adult CA Cancer J Clin, November 1, 2002; 52(6): 363 - 371. [Abstract] [Full Text] [PDF]

				A. H. Goldstone, A. K. Burnett, K. Wheatley, A. G. Smith, R. M. Hutchinson, and R. E. Clark Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial Blood, September 1, 2001; 98(5): 1302 - 1311. [Abstract] [Full Text] [PDF]

				E. H. Estey How I treat older patients with AML Blood, September 1, 2000; 96(5): 1670 - 1673. [Full Text] [PDF]

				W. Hiddemann, W. Kern, C. Schoch, C. Fonatsch, A. Heinecke, B. Wormann, and T. Buchner Management of Acute Myeloid Leukemia in Elderly Patients J. Clin. Oncol., November 1, 1999; 17(11): 3569 - 3576. [Abstract] [Full Text] [PDF]

				B. Lowenberg, J. R. Downing, and A. Burnett Acute Myeloid Leukemia N. Engl. J. Med., September 30, 1999; 341(14): 1051 - 1062. [Full Text] [PDF]

				G. Heil, D. Hoelzer, M. A. Sanz, K. Lechner, J. A. Liu Yin, G. Papa, L. Noens, J. Szer, A. Ganser, C. O'Brien, et al. A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Filgrastim in Remission Induction and Consolidation Therapy for Adults With De Novo Acute Myeloid Leukemia Blood, December 15, 1997; 90(12): 4710 - 4718. [Abstract] [Full Text] [PDF]

				R. M. Stone, D. T. Berg, S. L. George, R. K. Dodge, P. A. Paciucci, P. Schulman, E. J. Lee, J. O. Moore, B. L. Powell, C. A. Schiffer, et al. Granulocyte-Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia N. Engl. J. Med., June 22, 1995; 332(25): 1671 - 1677. [Abstract] [Full Text] [PDF]

				B. Lowenberg, W. van Putten, I. P. Touw, R. Delwel, and V. Santini Autonomous Proliferation of Leukemic Cells in Vitro as a Determinant of Prognosis in Adult Acute Myeloid Leukemia N. Engl. J. Med., March 4, 1993; 328(9): 614 - 619. [Abstract] [Full Text]